Targeted panel boosts accuracy of hereditary pancreatitis testing: Experts: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C.
About this episode
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.
(00:33)
Dr. Hasadsri, can you tell the audience a little bit about yourself and your background?
(01:32)
And Ms. Cabral?
(02:03)
Can you please give the audience a brief overview of this assay?
(03:33)
Which patients should have this testing and when should it be performed?
(04:23)
What alternative test options are available and how do these compare to our hereditary pancreatitis test?
(08:48)
How are results used in patient care?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab